Announces co-exclusive licensing agreement with Sanofi to co-commercialize COVID-19 vaccine, develop novel COVID-19-Influenza combination vaccines and develop multiple new vaccines utilizing Novavax's Matrix-MTM adjuvantThis agreement represents a potential multi-billion dollar revenue opportunity for Novavax including:$500 million upfront payment Approximately $70 million equity investment in NovavaxUp to $700 million in COVID-19 and combination product near-term milestones, plus ongoing tiered royalties on product salesUp to $200 million in milestones plus royalties for each new vaccine developed utilizing Novavax's Matrix-MTM adjuvantAnnounces addition of standalone influenza vaccine to Phase 3 COVID-19-Influenza Combination vaccine trial, which is on-track to initiate second half of 2024, with potential ...

Evolv Technology (NASDAQ: EVLV), the leading security technology company pioneering AI-based screening to create safer experiences, today announced financial results for the quarter ended March 31, 2024.

AEye, Inc. (NASDAQ: LIDR), a global leader in adaptive, high-performance lidar solutions, today announced that the non-binding Letter of Intent (“LOI”) announced in March is with LITEON Technology Corporation and is intended to provide AEye with a customer channel and industrialization partnership. Both companies will work together to supply AEye’s 4Sight™-based lidar products to automotive original equipment manufacturers (“OEMs”) who are focused on safety through automotive Advanced Driver Assistance Systems (“ADAS”). This is a logical collaboration as AEye continues to focus on its unique capital light business model, which leverages automotive Tier 1 partnerships to deliver AEye’s lidar solutions to ...

Inseego Corp. (Nasdaq: INSG) (the “Company”), a technology leader in 5G mobile and fixed wireless solutions for mobile network operators, Fortune 500 enterprises and SMBs, today reported its results for the first quarter ended March 31, 2024. The Company reported first quarter revenue of $45.0 million, GAAP operating loss of $1.7 million, GAAP net loss of $4.5 million, GAAP net loss of $(0.44) per share, and Adjusted EBITDA of positive $3.8 million. Unrestricted cash and cash equivalents at March 31, 2024 were $12.3 million.